MedTrace Logo

Pharmacokinetic Drug Interaction Study in Healthy Male Subjects

NCT01426906 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2011-09-01

No results posted yet for this study

Summary

A Randomized, Open Label, Drug-Drug interaction study to investigate effect of ketoconazole or rifampicin on the Pharmacokinetic characteristics and safety of LC15-0444 in Healthy Male Volunteers.

Conditions

  • Healthy Male Volunteers

Interventions

DRUG

Ketoconazole

Period 1 : LC15-0444 Period 2 : LC15-0444 with ketoconazole

DRUG

rifampicin

Period 1 : LC15-0444 Period 2 : LC15-0444 with rifampicin

Sponsors & Collaborators

  • LG Life Sciences

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01426906 on ClinicalTrials.gov